Saurabh Saha Sells 1,671 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 1,671 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $18.24, for a total value of $30,479.04. Following the sale, the chief executive officer now owns 575,661 shares of the company’s stock, valued at approximately $10,500,056.64. This trade represents a 0.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Saurabh Saha also recently made the following trade(s):

• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.89, for a total value of $928,950.00.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total transaction of $350,839.00.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.53, for a total transaction of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total transaction of $2,891,000.00.

Centessa Pharmaceuticals Stock Down 6.3 %

Shares of CNTA opened at $17.04 on Friday. The business’s 50 day moving average is $16.09 and its 200 day moving average is $12.40. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 12-month low of $5.58 and a 12-month high of $18.74. The company has a market capitalization of $1.93 billion, a PE ratio of -11.14 and a beta of 1.47.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. Research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares in the last quarter. Atria Investments Inc boosted its stake in Centessa Pharmaceuticals by 7.0% during the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after buying an additional 1,116 shares during the last quarter. GAMMA Investing LLC increased its stake in Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after acquiring an additional 1,509 shares during the last quarter. Quarry LP increased its stake in Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after acquiring an additional 3,108 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Centessa Pharmaceuticals by 99.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after acquiring an additional 6,785 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

CNTA has been the topic of several analyst reports. BMO Capital Markets lifted their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price for the company. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, Jefferies Financial Group increased their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.